Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

被引：0
|
作者：
Strand, Vibeke [1 ]
Purcaru, Oana [2 ]
van Vollenhoven, Ronald F. [3 ]
Choy, Ernest [4 ]
Fleischmann, Roy [5 ]
机构：
[1] Stanford Univ, Portola Valley, CA USA
[2] UCB Pharma, Brussels, Belgium
[3] Karolinska Inst, Stockholm, Sweden
[4] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1318
引用
收藏
页码：S567 / S567
页数：1
相关论文
共 50 条
  • [41] CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY
    Gladman, D.
    Fleischmann, R.
    Harris, K.
    Peterson, L.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 673 - 673
  • [42] CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY
    Gladman, D.
    Fleischmann, R.
    Harris, K.
    Peterson, L.
    Mease, P. J.
    VALUE IN HEALTH, 2016, 19 (07) : A594 - A594
  • [43] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Michael E. Thase
    Arielle D. Stanford
    Asli Memisoglu
    William Martin
    Amy Claxton
    J. Alexander Bodkin
    Madhukar H. Trivedi
    Maurizio Fava
    Miao Yu
    Sanjeev Pathak
    Neuropsychopharmacology, 2019, 44 : 2268 - 2276
  • [44] SUSTAINED EFFICACY AND LONG-TERM SAFETY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RESULTS OF A 5-YEAR, OPEN-LABEL EXTENSION STUDY
    Ashina, Messoud
    Goadsby, Peter J.
    Reuter, Uwe
    Silberstein, Stephen
    Dodick, David W.
    Xue, Fei
    Zhang, Feng
    Cheng, Sunfa
    Chou, Denise E.
    Lima, Gabriel Paiva da Silva
    CEPHALALGIA, 2020, 40 : 60 - 61
  • [45] Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    Petersenn, S.
    Salgado, L. R.
    Schopohl, J.
    Portocarrero-Ortiz, L.
    Arnaldi, G.
    Lacroix, A.
    Scaroni, C.
    Ravichandran, S.
    Kandra, A.
    Biller, B. M. K.
    ENDOCRINE, 2017, 57 (01) : 156 - 165
  • [46] Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
    Kavanaugh, Arthur
    Westhovens, Rene R.
    Winthrop, Kevin L.
    Lee, Susan J.
    Tan, YingMeei
    An, Di
    Ye, Lei
    Sundy, John S.
    Besuyen, Robin
    Meuleners, Luc
    Stanislavchuk, Mykola
    Spindler, Alberto J.
    Greenwald, Maria
    Alten, Rieke
    Genovese, Mark C.
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (08) : 1230 - 1238
  • [47] Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    S. Petersenn
    L. R. Salgado
    J. Schopohl
    L. Portocarrero-Ortiz
    G. Arnaldi
    A. Lacroix
    C. Scaroni
    S. Ravichandran
    A. Kandra
    B. M. K. Biller
    Endocrine, 2017, 57 : 156 - 165
  • [48] Cyclosporin vs leflunomide vs combination of two drugs in rheumatoid arthritis: Long-term optimal results of combination treatment from an open randomized study
    Karanikolas, G
    Charalambopoulos, D
    Andrianakos, A
    Antoniades, C
    Iakovou, M
    Fragiadaki, K
    Katsilambros, N
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 100 - 100
  • [49] Cyclosporin vs leflunomide vs combination of two drugs in rheumatoid arthritis: Long-term optimal results of combination treatment from an open randomized study
    Karanikolas, G
    Charalambopoulos, D
    Andrianakos, A
    Antoniades, C
    Iakovou, M
    Fragiadaki, K
    Katsilambros, N
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 180 - 181
  • [50] A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis of 4-year data)
    Klareskog, L
    Wajdula, J
    Pedersen, R
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 189 - 189
12345